6157-85-3 Usage
Description
[(2R,3S,4R,5R)-5-[(1-amino-2-formamido-ethylidene)amino]-3,4-dihydroxy-oxolan-2-yl]methoxyphosphonic acid, also known as fosfomycin, is a broad-spectrum antibiotic derived from the bacterium Streptomyces fradiae. It possesses bactericidal properties and is effective against a variety of gram-positive and gram-negative bacteria. Its unique mechanism of action involves inhibiting an essential enzyme in bacterial cell wall synthesis, leading to cell death. Fosfomycin is characterized by its safety profile and minimal side effects, making it a valuable addition to the antibiotic arsenal.
Uses
Used in Urinary Tract Infections:
Fosfomycin is used as a treatment for urinary tract infections (UTIs) due to its effectiveness against common uropathogens. It targets the bacterial cell wall synthesis, disrupting the integrity of the cell wall and leading to bacterial cell death. This action helps to clear the infection and alleviate symptoms associated with UTIs.
Used in Combination Therapy for Serious Infections:
In some cases, fosfomycin is used in combination with other antibiotics to treat more severe or complicated infections. The synergistic action of fosfomycin with other antibiotics can enhance the overall efficacy of the treatment, making it a valuable component in the management of serious bacterial infections.
Used in Oral and Intravenous Formulations:
Fosfomycin is available in both oral and intravenous formulations, allowing for flexible treatment options depending on the severity of the infection and the patient's condition. The oral formulation provides a convenient and non-invasive method of administration, while the intravenous formulation can be used for more severe cases that require rapid and direct delivery of the antibiotic to the bloodstream.
Used in the Pharmaceutical Industry:
Fosfomycin is used as an active pharmaceutical ingredient in the development and production of antibiotics. Its unique mechanism of action and broad-spectrum activity make it an important component in the fight against bacterial infections. The pharmaceutical industry continues to research and develop new formulations and combinations of fosfomycin to improve its efficacy and address the growing challenge of antibiotic resistance.
Check Digit Verification of cas no
The CAS Registry Mumber 6157-85-3 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 6,1,5 and 7 respectively; the second part has 2 digits, 8 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 6157-85:
(6*6)+(5*1)+(4*5)+(3*7)+(2*8)+(1*5)=103
103 % 10 = 3
So 6157-85-3 is a valid CAS Registry Number.
6157-85-3Relevant articles and documents
Mass spectrometric analysis of purine de novo biosynthesis intermediates
Mádrová, Lucie,Krijt, Matyá?,Bare?ová, Veronika,Václavík, Jan,Friedecky, David,Dobe?ová, Dana,Sou?ková, Olga,?kopová, Václava,Adam, Tomá?,Zikánová, Marie
, (2018)
Purines are essential molecules for all forms of life. In addition to constituting a backbone of DNA and RNA, purines play roles in many metabolic pathways, such as energy utilization, regulation of enzyme activity, and cell signaling. The supply of purines is provided by two pathways: the salvage pathway and de novo synthesis. Although purine de novo synthesis (PDNS) activity varies during the cell cycle, this pathway represents an important source of purines, especially for rapidly dividing cells. A method for the detailed study of PDNS is lacking for analytical reasons (sensitivity) and because of the commercial unavailability of the compounds. The aim was to fully describe the mass spectrometric fragmentation behavior of newly synthesized PDNS-related metabolites and develop an analytical method. Except for four initial ribotide PDNS intermediates that preferentially lost water or phosphate or cleaved the forming base of the purine ring, all the other metabolites studied cleaved the gly-cosidic bond in the first fragmentation stage. Fragmentation was possible in the third to sixth stages. A liquid chromatography-high-resolution mass spectrometric method was developed and applied in the analysis of CRISPR-Cas9 genome-edited HeLa cells deficient in the individual enzymatic steps of PDNS and the salvage pathway. The identities of the newly synthesized intermediates of PDNS were confirmed by comparing the fragmentation patterns of the synthesized metabolites with those produced by cells (formed under pathological conditions of known and theoretically possible defects of PDNS). The use of stable isotope incorporation allowed the confirmation of fragmentation mechanisms and provided data for future fluxomic experiments. This method may find uses in the diagnosis of PDNS disorders, the investigation of purinosome formation, cancer research, enzyme inhibition studies, and other applications.
